The St Mark’s Centre for Familial Intestinal Cancer (incorporating the Polyposis Registry and Family Cancer Clinic) 

The St Mark’s Centre for Familial Intestinal Cancer (incorporating the Polyposis Registry and Family Cancer Clinic) is run by a team of specialists consisting of Colorectal Surgeons, Gastroenterologists, Nurse Practitioners, Nurse Specialists and Administrators. The team works together to ensure prompt diagnosis and surveillance of patients with a genetic condition associated with bowel cancer or from a family at high risk of bowel and other cancers.

Breast Cancer Treatment’s Collateral Damage – Let’s Talk about it….

Citizenship rights and obligations

In my view as a citizen of Ireland I have certain rights and obligations.

One of my obligations is to do my best to protect myself and society.

I want people to have access to proper care in our Health system.

Nobody wants a situation where you can not get access to an intensive care bed.

The result of people not receiving a covid vaccination and contracting Covid -will ensure an intensive care bed usage way in excess of what the requirement should be.

Everyone suffers…

Implementing Lynch syndrome testing and surveillance pathways

Lynch Syndrome is the most common form of hereditary colorectal cancer.

By implementing Lynch syndrome pathways nationally for both colorectal and endometrial cancer there is the opportunity to detect many of these at an earlier stage and also prevent cancers through risk reduction treatments and appropriate surveillance routes.

Guidance on management of Lynch syndrome published by NHS UK (July 2021).

Click to access B0622-implementing-lynch-syndrome-testing-and-surveillance-pathways.pdf

PSA Screening for Aggressive Prostate Cancer Supported in Men With Lynch Syndrome

Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen (PSA) screening from age 40 to identify men with clinically significant prostate cancer, according to the initial results of the IMPACT study (NCT00261456) that were published in The Lancet Oncology.1

https://www.onclive.com/view/psa-screening-for-aggressive-prostate-cancer-supported-in-men-with-lynch-syndrome-associated-pathogenic-variants

Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome

Conclusions: Familial burden – in addition to age, sex, and specific LS gene – should be used to assess LS carriers’ risks of specific cancers and guide decision-making about organ-specific surveillance.

https://pubmed.ncbi.nlm.nih.gov/33794268/

Conquering cancer by targeting its genetic abnormalities

“Some say, ‘Oh, I don’t want to know.’ And I think, well, you’re nuts because knowledge is power, and you can stay ahead of this,” 

https://individualizedmedicineblog.mayoclinic.org/2020/11/11/conquering-cancer-by-targeting-its-genetic-abnormalities/?linkId=121710641